Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Alan W. Dunton

At a glance: Alan W. Dunton is Director at CorMedix (CRMD). Their latest SEC Form 4, filed Jan 2, 2026, reported a sale of $260K. On file: 0 purchase lines ($0) and 1 sale line ($260K).

Disclosed holdings: about $203K of CRMD stock: 40,250 shares reported on their latest Form 4 (filed Jan 2, 2026), valued at the Nov 19, 2026 close of $5.04. This counts only CRMD shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at CorMedix Inc. (CRMD)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $260K

Alan W. Dunton's InsiderPrint

5 trades from SEC Form 4 filings, 2020 to 2025, drawn as one fingerprint.

InsiderPrint of Alan W. Dunton: 5 trades, 2020 to 20252020: 1 buy, 0 sales2021: 0 buys, 0 sales2022: 0 buys, 0 sales2023: 2 buys, 0 sales2024: 0 buys, 0 sales2025: 1 buy, 1 sale

Reading this print: Mostly buys, trading about once a year, typically $20K a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (4)
  • Dent inward: a sale (1)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Denise L. DevineDirector · SLQT · 98% match
  2. Stephen T. WillsCFO, COO · PTN · 97% match
  3. James OfferdahlDirector · LAW · 95% matchTheir buys since 2023: 3 of 3 beat the S&P 500
  4. Joseph TodiscoCEO · CRMD · 92% matchTheir buys since 2020: 5 of 7 beat the S&P 500
  5. Alexander A. FitzpatrickGeneral Counsel · SPRY · 89% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2020

From the SEC's insider data sets: each open-market buy by Alan W. Dunton, matched to how the stock did over the next 90 days against the S&P 500.

2 of 3 buys beat the S&P 500 (67%), median +9.2% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
CRMDDec 18, 2023+9.2%
CRMDMay 19, 2023-24.2%
CRMDAug 20, 2020+36.8%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Jan 2SEC CRMDCorMedix Inc. Sell Plan 20,00040,250 held (−33%) $13.00 $260K -61.3%
  • Sell

    Director Alan W Dunton sold $260K of CRMD at $13.00 — cuts the stake by 33%; pre-scheduled 10b5-1 plan sale.

Follow Alan W. Dunton

Get one email when Alan W. Dunton files a new purchase or sale. Free.

At most one email a day about Alan W. Dunton, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.